2seventy bio’s (TSVT) “Sell (D-)” Rating Reaffirmed at Weiss Ratings

Weiss Ratings reiterated their sell (d-) rating on shares of 2seventy bio (NASDAQ:TSVT) in a report released on Wednesday,Weiss Ratings reports.

2seventy bio Price Performance

Shares of TSVT stock opened at $2.61 on Wednesday. 2seventy bio has a 1-year low of $2.29 and a 1-year high of $6.00. The stock’s 50-day moving average is $2.69 and its 200 day moving average is $3.83. The company has a market cap of $134.64 million, a P/E ratio of -1.40 and a beta of 1.74.

Institutional Investors Weigh In On 2seventy bio

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in TSVT. SG Americas Securities LLC purchased a new stake in 2seventy bio in the third quarter valued at about $80,000. GSA Capital Partners LLP purchased a new position in shares of 2seventy bio in the third quarter worth about $64,000. Intech Investment Management LLC purchased a new position in shares of 2seventy bio in the third quarter worth about $69,000. FMR LLC raised its stake in shares of 2seventy bio by 22.0% in the third quarter. FMR LLC now owns 148,545 shares of the company’s stock worth $701,000 after purchasing an additional 26,738 shares during the last quarter. Finally, BBR Partners LLC raised its stake in shares of 2seventy bio by 620.0% in the third quarter. BBR Partners LLC now owns 180,000 shares of the company’s stock worth $850,000 after purchasing an additional 155,000 shares during the last quarter. 93.90% of the stock is currently owned by hedge funds and other institutional investors.

About 2seventy bio

2seventy bio, Inc, a cell and gene therapy company, focuses on the research, development, and commercialization of treatments for cancer in the United States. The company's products pipeline includes Abecma, a chimeric antigen receptor T-cell product candidates for the treatment of multiple myeloma.